Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro

Filtros
- Dermatitis Atópica
- General

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

Comprehensive comparison between meningococcal conjugate and polysaccharide vaccines, highlighting the immunological advantages of conjugate vaccines including long-duration antibody response, memory B cell production, and herd immunity benefits. Essential information for healthcare providers, immunization specialists, and public health officials seeking evidence-based vaccine selection guidance.

IMD in South Africa: Provincial Analysis and National Trends

Current analysis of Invasive Meningococcal Disease (IMD) trends in South Africa, featuring provincial statistics, seasonal patterns, and mortality rates. Highlights significant 53% increase in cases from 2022 to 2023, with special focus on Western Cape's higher incidence rates and nationwide surveillance data from GERMS-SA programme.

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

SULIQUA - Uproszczenie Schematu Leczenia Cukrzycy.

Zapraszamy do zapoznania się z materiałem prezentującym SULIQUA® - innowacyjne rozwiązanie w leczeniu cukrzycy typu 2. Dowiedz się, jak można uprościć schemat leczenia, poprawić kontrolę glikemii i zredukować ryzyko hipoglikemii przy jednym wstrzyknięciu dziennie. Materiał zawiera kluczowe informacje o skuteczności terapii i jej wpływie na jakość życia pacjentów.

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 5 of 10: The benefits of early combination therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 8 of 10: Benefits of early combination therapy of GLP-1 and basal

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 9 of 10: Benefits of a second-generation basal insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

«
‹
44
45
46
47
48
49
50
51
52
53
›
»

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

MAT-CO-2400825 V1.0 03/2024

Page menu

Áreas terapeúticas

Patología

Filtros

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

IMD in South Africa: Provincial Analysis and National Trends

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

SULIQUA - Uproszczenie Schematu Leczenia Cukrzycy.

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Part 5 of 10: The benefits of early combination therapies

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies

Part 8 of 10: Benefits of early combination therapy of GLP-1 and basal

Part 9 of 10: Benefits of a second-generation basal insulin